
The Table-Integrated OR: How J&J OTTAVA's FDA Clearance Challenges Intuitive's Soft-Tissue Monopoly
Dr. Dereck Mush, MD, MBANo. 43 Investors
General Partner, Lux Capital • United States
Venture capitalist investing in intersectional health and emerging technologies.
Find on LinkedInHer investment portfolio and active publishing on maternal health, clinical infrastructure, and health equity have helped establish clinical outcomes as a primary measure of digital health success.
Venture capitalist investing in intersectional health and emerging technologies.
Her investment portfolio and active publishing on maternal health, clinical infrastructure, and health equity have helped establish clinical outcomes as a primary measure of digital health success.
Loading the full dossier
Audience size across LinkedIn, X, YouTube, podcasts and newsletters.
How much the audience actually reacts, comments, shares and subscribes.
Clinical, research, operating or investing track record behind the commentary.
Publishing cadence and how reliably they show up with original work.
Whether decision makers, policy and capital actually move on what they say.
Scores are subjective editorial estimates compiled by our research desk from public profiles and published work. They are opinion, not measurement, and they are not a judgement of any person's character or ability.
Christina FarrFounder and CEO, Second Opinion Media / Scrub Capital
Lisa SuennenManaging Partner, Venture Valkyrie
Julie YooGeneral Partner, Andreessen HorowitzChange, add or remove details on this profile. Our desk reviews every request.
This profile is compiled by our research desk from public sources and is published as editorial commentary. Want a correction, an update, or your profile removed? and see our corrections and removals policy.

Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBAKeep exploring